|
Liver Diseases, Parasitic
|
0.300 |
Biomarker
|
group |
CTD_human |
Exome sequencing of liver fluke-associated cholangiocarcinoma.
|
22561520 |
2012 |
|
Cholangiocarcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Exome sequencing of liver fluke-associated cholangiocarcinoma.
|
22561520 |
2012 |
|
Intrahepatic Cholangiocarcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Exome sequencing of liver fluke-associated cholangiocarcinoma.
|
22561520 |
2012 |
|
Extrahepatic Cholangiocarcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Exome sequencing of liver fluke-associated cholangiocarcinoma.
|
22561520 |
2012 |
|
Colorectal Carcinoma
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Leukemia, Myelocytic, Acute
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide haplotype association study identify the FGFR2 gene as a risk gene for acute myeloid leukemia.
|
27903959 |
2017 |
|
Neoplasms
|
0.090 |
GeneticVariation
|
group |
BEFREE |
We previously discovered that systemic delivery of decorin for treatment of breast carcinoma xenografts induces paternally expressed gene 3 (Peg3), an imprinted gene encoding a zinc finger transcription factor postulated to function as a tumor suppressor.
|
28174297 |
2017 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Ovarian cancer cells (Hey and SKOv3) were treated with demethylating agents (5-aza-20-deoxycytidine [DAC] or 5-azacitidine [AZA]) or with HDAC inhibitors (suberoylanilide hydroxamicacid [SAHA] or trichostatin A [TSA]) to determine their impact on cellular proliferation, cell cycle regulation, apoptosis, autophagy, and re-expression of 2 growth inhibitory imprinted tumor suppressor genes: guanosine triphosphate-binding Di-RAS-like 3 (ARHI) and paternally expressed 3 (PEG3).
|
21491416 |
2011 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Hypermethylation of the PEG3 promoter in primary human gliomas led to a loss of imprinting and decreased PEG3 mRNA expression that correlated with tumor grade.
|
20064927 |
2010 |
|
Neoplasms
|
0.090 |
GeneticVariation
|
group |
BEFREE |
Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
|
18286529 |
2008 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Given the known role of PEG3 in p53-mediated apoptosis, it is possible that PEG3 functions as a tumor suppressor.
|
16023706 |
2005 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
The human paternally expressed gene 3 (PEG3) on chromosome 19q13.4 is one of the candidate tumor suppressor genes for glioma.
|
15141944 |
2004 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Recently it was reported that a novel rat Gadd34-related gene, PEG-3, was upregulated in transformed cells, and that forced expression of this gene led to increased tumorigenic potential of cells implanted into nude mice and increased angiogenesis of these tumors.
|
12813455 |
2003 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Introduction of PEG3 cDNA into the glioma cells suggests that human PEG3 protein functions as a tumour suppressor.
|
11260267 |
2001 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
We presently demonstrate that forced expression of PEG-3 in tumorigenic rodent cells, and in human cancer cells, increases their oncogenic potential in nude mice as reflected by a shorter tumor latency time and the production of larger tumors with increased vascularization.
|
10611347 |
1999 |
|
Malignant Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
However, intratumoral injections of a conditionally replication-competent Ad (CRCA) in which expression of the adenoviral E1A gene is driven by the cancer-specific promoter of progression-elevated gene-3 (PEG-3) and which simultaneously expresses mda-7/interleukin (IL)-24 in the E3 region of the Ad (Ad.PEG-E1A-mda-7), a cancer terminator virus (CTV), is highly active in these cells.
|
19888195 |
2010 |
|
Primary malignant neoplasm
|
0.080 |
Biomarker
|
group |
BEFREE |
However, intratumoral injections of a conditionally replication-competent Ad (CRCA) in which expression of the adenoviral E1A gene is driven by the cancer-specific promoter of progression-elevated gene-3 (PEG-3) and which simultaneously expresses mda-7/interleukin (IL)-24 in the E3 region of the Ad (Ad.PEG-E1A-mda-7), a cancer terminator virus (CTV), is highly active in these cells.
|
19888195 |
2010 |
|
Malignant Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
To develop an approach to effectively treat this aggressive disease, we constructed a conditionally replication-competent adenovirus in which expression of the adenoviral E1A gene, necessary for replication, is driven by the cancer-specific promoter of progression-elevated gene-3 (PEG-3) and which simultaneously expresses mda-7/IL-24 in the E3 region of the adenovirus (Ad.PEG-E1A-mda-7), a cancer terminator virus (CTV).
|
18323853 |
2008 |
|
Primary malignant neoplasm
|
0.080 |
Biomarker
|
group |
BEFREE |
To develop an approach to effectively treat this aggressive disease, we constructed a conditionally replication-competent adenovirus in which expression of the adenoviral E1A gene, necessary for replication, is driven by the cancer-specific promoter of progression-elevated gene-3 (PEG-3) and which simultaneously expresses mda-7/IL-24 in the E3 region of the adenovirus (Ad.PEG-E1A-mda-7), a cancer terminator virus (CTV).
|
18323853 |
2008 |
|
Malignant Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
We constructed a conditionally replication-competent adenovirus in which expression of the adenoviral E1A gene, necessary for replication, is driven by the cancer-specific promoter of progression elevated gene-3 (PEG-3) and which simultaneously expresses mda-7/IL-24 in the E3 region of the adenovirus (Ad.PEG-E1A-mda-7), a cancer terminator virus (CTV).
|
17545625 |
2007 |
|
Primary malignant neoplasm
|
0.080 |
Biomarker
|
group |
BEFREE |
We constructed a conditionally replication-competent adenovirus in which expression of the adenoviral E1A gene, necessary for replication, is driven by the cancer-specific promoter of progression elevated gene-3 (PEG-3) and which simultaneously expresses mda-7/IL-24 in the E3 region of the adenovirus (Ad.PEG-E1A-mda-7), a cancer terminator virus (CTV).
|
17545625 |
2007 |
|
Malignant Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Progression-elevated gene-3 (PEG-3) is a rodent gene identified by subtraction hybridization that displays elevated expression as a function of transformation by diversely acting oncogenes, DNA damage, and cancer cell progression.
|
15647352 |
2005 |
|
Malignant Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
We currently describe an adenovirus-based therapy for successfully managing pancreatic cancer, the cancer terminator virus (CTV), which is founded on targeted induction of viral replication from a cancer-specific progression elevated gene-3 (PEG-3) promoter (PEG-Prom) and immune modulation by IFN-gamma.
|
16204080 |
2005 |
|
Primary malignant neoplasm
|
0.080 |
Biomarker
|
group |
BEFREE |
We currently describe an adenovirus-based therapy for successfully managing pancreatic cancer, the cancer terminator virus (CTV), which is founded on targeted induction of viral replication from a cancer-specific progression elevated gene-3 (PEG-3) promoter (PEG-Prom) and immune modulation by IFN-gamma.
|
16204080 |
2005 |
|
Primary malignant neoplasm
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Progression-elevated gene-3 (PEG-3) is a rodent gene identified by subtraction hybridization that displays elevated expression as a function of transformation by diversely acting oncogenes, DNA damage, and cancer cell progression.
|
15647352 |
2005 |